Your browser doesn't support javascript.
loading
Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
Xu, Manyi; Shao, Keda; Wang, Yanhua; Hao, Yue; Song, Zhengbo.
Afiliação
  • Xu M; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310000, China.
  • Shao K; Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
  • Wang Y; Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
  • Hao Y; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310018, Zhejiang, China.
  • Song Z; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310000, China.
Clin Transl Oncol ; 26(7): 1687-1695, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38363527
ABSTRACT

BACKGROUND:

Anlotinib, as a salvage treatment for patients after failure of third-line or later-line treatments for small cell lung cancer (SCLC), has shown efficacy in patients with brain metastases (BMs). However, the efficacy and safety of anlotinib alone or in combination with immunotherapy for SCLC with BMs remain unclear.

METHOD:

Patients treated with anlotinib alone or in combination with an immune checkpoint inhibitor (ICI) at the Zhejiang Cancer Hospital between April 2019 and February 2023 were identified. Kaplan-Meier curves were used to describe the progression-free survival (PFS) and intracranial PFS (iPFS). A waterfall diagram was used to indicate changes in intracranial lesions.

RESULTS:

A total of 48 patients were included; 29 received anlotinib alone, and 19 were administered anlotinib plus ICI. Combination therapy, compared with anlotinib, was associated with significantly longer PFS and iPFS (PFS 8.1 months vs. 2.5 months, P < 0.001; iPFS 8.1 months vs. 2.5 months, P = 0.004). Similar results were observed in patients with multiple BMs (PFS 8.1 months vs. 1.9 months, P = 0.001; iPFS 8.1 months vs. 1.9 months, P = 0.002). After third-line or later-line treatments, patients treated with ICI plus anlotinib also achieved significant PFS and iPFS benefits (PFS 8.4 months vs. 2.1 months, P < 0.001; iPFS 9.2 months vs. 2.1 months, P = 0.002). No new or severe adverse events were observed with combination therapy.

CONCLUSION:

The combination of anlotinib and ICI has promising intracranial and extracranial efficacy with tolerable toxicity, and may be a therapeutic option for SCLC patients with BMs.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pequenas Células do Pulmão / Inibidores de Checkpoint Imunológico / Indóis / Neoplasias Pulmonares Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pequenas Células do Pulmão / Inibidores de Checkpoint Imunológico / Indóis / Neoplasias Pulmonares Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Itália